DPAt a glance
Core facts about the doctor and the hospital, as provided by the hospital.
1 areaSpecialties: Medical director and president of the Instituto Oncológico. Hospital Universitari Dexeus · Grupo Quirónsalud
OncologyCategory
English, SpanishLanguages
JCIAccredited hospital · Madrid
US$940 from5 priced items
35 staffListed at this hospital
Dr. Rafael Rosell is a Medical director and president of the Instituto Oncológico. Hospital Universitari Dexeus · Grupo Quirónsalud at Grupo Quirónsalud in Madrid, Spain, a JCI-accredited center. Lists Medical director and president of the Instituto Oncológico. Hospital Universitari Dexeus · Grupo Quirónsalud. The hospital lists prices from US$940.
About
Dr. Rosell is a specialist in medical oncology, with advanced training in lung cancer (non-small cell lung cancer). In 1982, he completed his residency at Memorial Sloan-Kettering Cancer Center, in New York, under Dr R. Gralla, Dept. of medicine (developmental chemotherapy).
Memberships in International scientific associations: European Society for Medical Oncology (ESMO). American Society of Clinical Oncology (ASCO). International Association for the Study of Lung Cancer (IASLC). European Organization for Research and Treatment of Cancer (EORTC). Spanish Lung Cancer Group (President, 1991-2014). No. of publications in first-quartile International journals , 3,200 total publications in the 1st quartile (over 40 years of practice). The 2 most important, for which Dr Rosell was the main author, are: “Erlotinib versus chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial” Lancet Oncology 2012 Mar;13(3):239-246. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009 Sep 3;361(10):958-67. doi: 10.1056/NEJMoa0904554
No. of patents (participated in securing): 18.
Memberships in International scientific associations: European Society for Medical Oncology (ESMO). American Society of Clinical Oncology (ASCO). International Association for the Study of Lung Cancer (IASLC). European Organization for Research and Treatment of Cancer (EORTC). Spanish Lung Cancer Group (President, 1991-2014). No. of publications in first-quartile International journals , 3,200 total publications in the 1st quartile (over 40 years of practice). The 2 most important, for which Dr Rosell was the main author, are: “Erlotinib versus chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial” Lancet Oncology 2012 Mar;13(3):239-246. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009 Sep 3;361(10):958-67. doi: 10.1056/NEJMoa0904554
No. of patents (participated in securing): 18.
Ask the doctor's team about your case
Send your reports and questions to Grupo Quirónsalud. The hospital replies through Health-Tourism.com.
Free consultation • No obligation • Direct communication with the hospital
